Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 442

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 442
---
 |      (5,094 | ) |
| Net loss attributable to common stockholders               |     | $               | (22,648,903 | ) |     | $          | (6,514,939 | ) |     |             |            |     |     | $            | (36,362,071 | ) |     | $            | (17,131,527 | ) |     |             |            |       |     | $         | (58,827,514 | ) |
| Basic and fully diluted loss per share                     |     | $               |       (1.21 | ) |     | $          |      (0.25 | ) |     |             |            |     |     |              |             |   |     | $            |       (1.42 | ) |     |             |            |       |     |           |             |   |
| Basic and fully diluted weighted average number of shares  |     |                 |  18,663,000 |   |     |            | 26,352,000 |   |     |             |            |     |     |              |             |   |     |              |  12,100,000 |   |     |             |            |       |     |           |             |   |
| Net loss per share - basic and diluted (See Note 5)        |     |                 |             |   |     |            |            |   |     |             |            |     |     |              |       (0.86 | ) |     |              |             |   |     |             |            |       |     |           |       (1.12 | ) |
| Weighted average shares outstanding - basic and diluted(1) |     |                 |             |   |     |            |            |   |     |             |            |     |     |              |  42,284,525 |   |     |              |             |   |     |             |            |       |     |           |  52,737,094 |   |

| (1) | Based on the 1-35 reverse share split effected at the discretion of Kintara’s Board of Directors immediately prior to the consummation of the Kintara Merger on October 18, 2024 (see Note 5). |

See accompanying notes to the unaudited pro forma condensed combined financial statements.

F-182

NOTES TO